Literature DB >> 7487077

Recombinant human dihydroorotate dehydrogenase: expression, purification, and characterization of a catalytically functional truncated enzyme.

R A Copeland1, J P Davis, R L Dowling, D Lombardo, K B Murphy, T A Patterson.   

Abstract

An N-terminally truncated cDNA for human dihydroorotate dehydrogenase (DHODase) was placed under the control of the inducible T7 lac promoter in a pyrimidine auxotrophic strain of Escherichia coli lacking the endogenous enzyme. Induction of gene expression rescued growth in media lacking exogenous pyrimidines. The recombinant enzyme was purified to homogeneity from detergent extracts of bacterial membranes by two chromatographic steps. The purity of the resulting enzyme was judged to be > 95% based on SDS-PAGE with Coomassie staining. The enzyme displays an apparent molecular weight of ca. 40 kDa on SDS-PAGE and ca. 120 kDa on native size-exclusion chromatography, suggesting that the native enzyme is multimeric. Recombinant DHODase displayed a specific activity and Km for dihydroorotate that were similar to those for the enzymes from bovine and human liver tissue. The pH dependence of the activity of the recombinant enzyme was likewise similar to that of the enzyme from human liver and may indicate the involvement of a critical histidine residue in catalytic turnover; only eight histidine residues remain in the truncated version of DHODase used here. The catalytic activity of the recombinant enzyme is inhibited in a dose-dependent fashion by the histidine-selective modifying agent diethylpyrocarbonate. These results further suggest a potential role for histidine in enzyme turnover. Brequinar sodium, an experimental drug which has been shown to be a nanomolar noncompetitive inhibitor of mammalian DHODases, inhibited the activity of the purified recombinant enzyme with a Ki value similar to that for enzyme derived from human liver tissue. The recombinant DHODase thus displays enzymatic behavior similar to the 50-kDa full-length human liver enzyme, illustrating that the catalytically essential structural features of the enzyme, as well as the site of Brequinar binding, are contained within the 40-kDa truncated version of the enzyme that was expressed here.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7487077     DOI: 10.1006/abbi.1995.0012

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  11 in total

Review 1.  Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy.

Authors:  Margaret A Phillips; Pradipsinh K Rathod
Journal:  Infect Disord Drug Targets       Date:  2010-06

2.  F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase.

Authors:  Jason D Oliver; Graham E M Sibley; Nicola Beckmann; Katharine S Dobb; Martin J Slater; Laura McEntee; Saskia du Pré; Joanne Livermore; Michael J Bromley; Nathan P Wiederhold; William W Hope; Anthony J Kennedy; Derek Law; Mike Birch
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-25       Impact factor: 11.205

3.  (R)-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells.

Authors:  Dalia Barsyte-Lovejoy; Fengling Li; Menno J Oudhoff; John H Tatlock; Aiping Dong; Hong Zeng; Hong Wu; Spencer A Freeman; Matthieu Schapira; Guillermo A Senisterra; Ekaterina Kuznetsova; Richard Marcellus; Abdellah Allali-Hassani; Steven Kennedy; Jean-Philippe Lambert; Amber L Couzens; Ahmed Aman; Anne-Claude Gingras; Rima Al-Awar; Paul V Fish; Brian S Gerstenberger; Lee Roberts; Caroline L Benn; Rachel L Grimley; Mitchell J S Braam; Fabio M V Rossi; Marius Sudol; Peter J Brown; Mark E Bunnage; Dafydd R Owen; Colby Zaph; Masoud Vedadi; Cheryl H Arrowsmith
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-18       Impact factor: 11.205

4.  Inhibition of dengue virus through suppression of host pyrimidine biosynthesis.

Authors:  Qing-Yin Wang; Simon Bushell; Min Qing; Hao Ying Xu; Aurelio Bonavia; Sandra Nunes; Jing Zhou; Mee Kian Poh; Paola Florez de Sessions; Pornwaratt Niyomrattanakit; Hongping Dong; Keith Hoffmaster; Anne Goh; Shahul Nilar; Wouter Schul; Susan Jones; Laura Kramer; Teresa Compton; Pei-Yong Shi
Journal:  J Virol       Date:  2011-04-20       Impact factor: 5.103

5.  Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide.

Authors:  J M Bruneau; C M Yea; S Spinella-Jaegle; C Fudali; K Woodward; P A Robson; C Sautès; R Westwood; E A Kuo; R A Williamson; E Ruuth
Journal:  Biochem J       Date:  1998-12-01       Impact factor: 3.857

6.  Structural plasticity of malaria dihydroorotate dehydrogenase allows selective binding of diverse chemical scaffolds.

Authors:  Xiaoyi Deng; Ramesh Gujjar; Farah El Mazouni; Werner Kaminsky; Nicholas A Malmquist; Elizabeth J Goldsmith; Pradipsinh K Rathod; Margaret A Phillips
Journal:  J Biol Chem       Date:  2009-07-28       Impact factor: 5.157

7.  Analysis of flavin oxidation and electron-transfer inhibition in Plasmodium falciparum dihydroorotate dehydrogenase.

Authors:  Nicholas A Malmquist; Ramesh Gujjar; Pradipsinh K Rathod; Margaret A Phillips
Journal:  Biochemistry       Date:  2008-01-29       Impact factor: 3.162

8.  Identification of a small molecule that simultaneously suppresses virulence and antibiotic resistance of Pseudomonas aeruginosa.

Authors:  Qiaoyun Guo; Yu Wei; Bin Xia; Yongxin Jin; Chang Liu; Xiaolei Pan; Jing Shi; Feng Zhu; Jinlong Li; Lei Qian; Xinqi Liu; Zhihui Cheng; Shouguang Jin; Jianping Lin; Weihui Wu
Journal:  Sci Rep       Date:  2016-01-11       Impact factor: 4.379

9.  Fluorescence assay of dihydroorotate dehydrogenase that may become a cancer biomarker.

Authors:  Sheng Yin; Tsutomu Kabashima; Qinchang Zhu; Takayuki Shibata; Masaaki Kai
Journal:  Sci Rep       Date:  2017-01-13       Impact factor: 4.379

10.  Dihydroorotate dehydrogenase Inhibitors Target c-Myc and Arrest Melanoma, Myeloma and Lymphoma cells at S-phase.

Authors:  Mathura Subangari Dorasamy; Bhavesh Choudhary; Kavitha Nellore; Hosahalli Subramanya; Pooi-Fong Wong
Journal:  J Cancer       Date:  2017-09-05       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.